Abstract
Tofacitinib, an oral Janus kinase inhibitor, has demonstrated
teratogenic effects in animal models. However, there is a lack of data
on its effects during human pregnancy, especially in the context of
synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome, a
rare disease. We report a case of a 31-year-old female patient with
SAPHO syndrome who became pregnant unexpectedly after 5 weeks of
continuous tofacitinib treatment during the first trimester. Tofacitinib
was immediately discontinued upon discovering the pregnancy. The patient
successfully delivered a healthy full-term male infant under vigilant
monitoring, and her SAPHO syndrome symptoms ameliorated during gestation
but exacerbated 40 days postpartum. Given the limited clinical data
available, further monitoring of pregnancy outcomes in patients treated
with tofacitinib is still warranted.